However, some studies have reported that amplification of NCOA3 appears to be independently associated with poor prognosis in patients with hepatocellular carcinoma, and moderate or high expression of NCOA3 is associated with poor disease‐specific survival in patients with prostate disease (Gnanapragasam et al., 2001; Song et al., 2012). The gene discussed is NCOA3; the disease is hepatocellular carcinoma.